Drug Profile
Research programme: anti-cancer protein therapeutics - Five Prime Therapeutics
Alternative Names: FPA 005; FPT 040; FPT 047Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Galaxy Biotech
- Developer Five Prime Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotherapies; Monoclonal antibodies; Proteins
- Mechanism of Action Protein modulators; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer; Gastric cancer
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastric-cancer in USA (Parenteral)